Cognition

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Retrieved on: 
Thursday, February 22, 2024
Epilepsy, Pharmacology, DSM-IV codes, Research, GABAA, Drug resistance, 300X, Dizziness, Drug development, PAM, Volunteering, GAERS, Risk, Generalized tonic–clonic seizure, Deficit spending, Rat, Therapy, Ataxia, Memory, MED, Human, Cognition, Patient, Somnolence, Addiction, Partnership, Pharmaceutical industry

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.

Key Points: 
  • MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.
  • The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model.
  • The study demonstrated full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg.
  • “The preclinical data published in Drug Development Research demonstrate BAER-101’s ability to fully suppress seizures in the GAERS model, a translational animal model for anti-seizure drug development with a documented high predictability of response in humans.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 22, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Tuesday, February 20, 2024
Pomerantz, City University, Court, Person, FDA, News, Data management, Neurobiology of Aging, Complaint, District court, Ext, Initiative, Safety, Cassava, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, Action Replay, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

Retrieved on: 
Tuesday, February 20, 2024
BBB, Traffic barrier, Messenger, Voyager, Conference, MicroRNA, RNA, Therapy, Pharmacokinetics, Patient, Cognition, VY, IND, AAV, DSM-IV codes, PET, Mouse, Brain, Vaccine

LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy program will be presented at the upcoming 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024), taking place March 5-9, 2024, in Lisbon, Portugal.

Key Points: 
  • Tau Silencing Gene Therapy Program:
    Intravenous administration of BBB-penetrant AAV containing primary artificial microRNA targeting tau reduces tau broadly and robustly in hTau mouse brain.
  • Voyager’s tau silencing gene therapy program combines vectorized tau-targeted siRNA with a proprietary, blood-brain barrier (BBB)-penetrant capsid derived from the Company’s TRACER™ discovery platform.
  • Based on these data, Voyager has advanced this program into late research and expects to file an investigational new drug (IND) application in 2026.
  • Pharmacokinetics and tolerability of VY-TAU01, an anti-tau antibody for the treatment of Alzheimer’s disease, in P301S mouse and nonhuman primate.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, February 18, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference

Retrieved on: 
Thursday, March 7, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Facial expression, PD, Doctor of Philosophy, Computation, CST, Cognition, Neurodegenerative disease, Conference, Nadolol, Safety, Attention, Social cognition, Biomarker, Therapy, Memory, Dementia, Facial recognition, Function (mathematics), MCI, Tablet, DSM-IV codes, DNA, Brain, Pharmaceutical industry

The oral presentation will take place at AD/PD™ 2024: The International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held March 5-9, 2024, in Lisbon, Portugal.

Key Points: 
  • The oral presentation will take place at AD/PD™ 2024: The International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held March 5-9, 2024, in Lisbon, Portugal.
  • CST-2032 is one of CuraSen’s two lead product candidates being tested in patients with Alzheimer’s and Parkinson’s disease.
  • Both CST-2032 and CST-103 work by enabling reactivation of brain adrenergic function lost early in the neurodegenerative disease process.
  • Target effect sizes of 0.2-0.3 or higher, as seen in this study, predict success in larger, longer studies.

Pioneering work in computational and theoretical neuroscience is awarded the world’s largest brain research prize

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Other Science, Medical Devices, Research, Software, Science, Nervous system, Multimedia, AI, Neuroscience, Courage, Intelligence, Brain, Neuron, Schizophrenia, Language, Harvard University, Mathematics, Learning, Perception, Physics, Computation, Foundationalism, Memory, The Brain Prize, Cognition, Epilepsy, Knowledge, Imagination, Columbia University, Hebrew University of Jerusalem, Pharmaceutical industry

The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience.

Key Points: 
  • The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience.
  • View the full release here: https://www.businesswire.com/news/home/20240305504553/en/
    Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance.
  • The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
    Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.
  • Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:
    “It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience.

China Commercial Vehicle Intelligent Chassis Industry Report 2023: Both OEMs and Suppliers Now have Made Layout of Standardized Intelligent Chassis - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024
Automotive, General Automotive, Automotive Manufacturing, Other Automotive, Manufacturing, Performance & Special Interest, EBS, Electric vehicle, PIX, King Long, CTP, Intelligence, Research, WABCO, China South Industries Group, XCMG, Long March, EMC, Sany, EHB, Original equipment manufacturer, BAIC, Schaeffler Group, CIIC, Cell, JMC, GWM, Yutong, Qingling Motors, JAC, CATL, FAW Jiefang, Tongji University, Dongfeng, REE, Cognition, AICO, Mercedes-Benz Actros, PACK, CSGC, CTC, Commercial vehicle, Printed circuit board

Commercial Vehicle Intelligent Chassis Industry Report, 2023, combs through and researches status quo and related product layout of OEMs and suppliers, and predicts future development trends of commercial vehicle intelligent chassis.

Key Points: 
  • Commercial Vehicle Intelligent Chassis Industry Report, 2023, combs through and researches status quo and related product layout of OEMs and suppliers, and predicts future development trends of commercial vehicle intelligent chassis.
  • Referring to the Electric Vehicle Intelligent Chassis Technology Roadmap, currently the development of commercial vehicle intelligent chassis in China focuses on four components, namely, brake-by-wire, steer-by-wire, drive-by-wire, and intelligent suspension.
  • In the trend for commercial vehicle electrification, connection and intelligence, intelligent chassis, as a development cornerstone of vehicle intelligence, has become a development priority of the industry.
  • Driven by national policies and market demand, OEMs and suppliers have quickened their pace of deploying intelligent chassis to solve the current problem of 'insufficiently flexible limbs' in commercial vehicle chassis and support intelligent upgrade of commercial vehicle chassis.

Mountain Valley MD Provides Business Update, Appoints New CFO

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health, Pharmaceutical, Vitamins, Supplements, Agriculture, Natural Resources, Research, Fitness & Nutrition, Environment, Science, Veterinary, Deep Sleep, Animal, Growth, Commerce, Sale, Powder, Climate change, HLB, Eon, Farm, MVDM, Livestock, McGill University, Micronutrient, Plant, GMP, Tree, Eons.com, Nutraceutical, Immunity, Tablet, Photosynthesis, CW, CPA, FRA, Sleep, Calendar, Tilapia, Logic, Catfish, CFO, Ivermectin, Aquaculture, Fishery, Patent, Consultant, Biomass, Government, Licensee, Nutrient, Republic, Cognition, Citrus, Disease

The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.

Key Points: 
  • The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.
  • To date, the Company has worked on a range of formulations for Quicksome™-powered product applications, including sleep, energy, appetite suppressant, cognition, immunity, calm, and pain relief.
  • The Company believes this will be valuable in its business development efforts and broad growth plans for its nutraceutical line of business.
  • Since July 2009, his tenure at Malaspina Consultants Inc. has been marked by CFO and accounting roles for various public and private companies across multiple industries.

Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs

Retrieved on: 
Tuesday, March 5, 2024
Veterinary, Research, Pets, Clinical Trials, Biotechnology, Health, Consumer, General Health, Science, Pet, Doctor of Philosophy, Dementia, Quality of life, Ageing, Animal, Dog, Neurology, NCSU, Gene expression, Happiness, Cognition, Clinical trial, Frailty, Harvard Medical School, Genetics, BioRxiv, Human, Pharmaceutical industry

Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.

Key Points: 
  • Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
  • After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.
  • "The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted.
  • In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement.